Becoming a leading company in Japan’s regenerative medicine market
First written in FY2021. 2 of 3 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「We believe that our Group's business foundation will be strengthened by continuing, as a leading company, to drive the social implementation of regenerative medicine and conduct educational activities, including providing evidence-based information to medical institutions and patients.」
The policy of becoming a leading company driving the regenerative medicine market continued to be presented in connection with social implementation, evidence-based information provision and educational activities. - FY2022RestatedAnnual report
「We believe that continuing to lead the regenerative medicine market as a leading company by investing appropriate human resources and capital will contribute to business expansion and financial stability.」
The objective of investing human resources and capital to become a leading company driving the regenerative medicine market remains in place. - FY2021First statedAnnual report
「We believe that continuing to lead the regenerative medicine market as a leading company by investing appropriate human resources and capital will contribute to business expansion and financial stability.」
A new objective was explicitly stated: to invest human resources and capital and become a leading company driving Japan's regenerative medicine market.